WST
West Pharmaceutical Services Inc
NYSE: WST · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$322.30
-0.89% today
Updated 2026-06-05
Market cap
$23.23B
P/E ratio
44.08
P/S ratio
7.21x
EPS (TTM)
$7.46
Dividend yield
0.26%
52W range
$206 – $337
Volume
0.9M
WallStSmart proprietary scores
65
out of 100
Grade: B
Buy
Investment rating
7.3
Growth
B+8.5
Quality
A8.0
Profitability
A2.7
Valuation
F4/9
Piotroski F-Score
Moderate
4.7
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$358.79
+11.32%
12-Month target
$203.74
-36.79%
Intrinsic (DCF)
$157.79
Margin of safety
-56.00%
2 Strong Buy10 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.73 — safe zone
+ Free cash flow $47.20M — positive
+ Revenue growth 21.00% QoQ
+ Debt/equity 0.11x — low leverage
Risks
- 56.00% above intrinsic value
- P/E 44.08x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.89B | $2.95B | $2.89B | $3.07B | $3.22B |
| Net income | $585.90M | $593.40M | $492.70M | $493.70M | $138.80M |
| EPS | — | — | — | — | $7.46 |
| Free cash flow | $439.40M | $414.50M | $276.40M | $468.90M | $47.20M |
| Profit margin | 20.30% | 20.11% | 17.03% | 16.06% | 16.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-12 | CAMPBELL, SHANE ALDEN | Sale | 474 | — |
| 2026-05-12 | CAMPBELL, SHANE ALDEN | Sale | 296 | — |
| 2026-05-12 | CAMPBELL, SHANE ALDEN | Buy | 474 | — |
Peer comparison
Smart narrative
West Pharmaceutical Services Inc trades at $322.30. representing a P/E of 44.08x trailing earnings. Our Smart Value Score of 65/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 4.73, it sits in the safe zone. TTM revenue stands at $3.22B. with profit margins at 16.90%. Our DCF model estimates intrinsic value at $157.79.
Frequently asked questions
What is West Pharmaceutical Services Inc's stock price?
West Pharmaceutical Services Inc (WST) trades at $322.30, on a P/E of 44.1x and a P/S of 7.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is West Pharmaceutical Services Inc overvalued?
West Pharmaceutical Services Inc carries a Smart Value Score of 65/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $157.79 against the $322.30 price, so on cash flow terms the market is paying a premium for West Pharmaceutical Services Inc's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of West Pharmaceutical Services Inc (WST)?
The 12-month analyst consensus target is $358.79, about 11.3% above the current $322.30. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of West Pharmaceutical Services Inc (WST)?
Our DCF model estimates intrinsic value at $157.79, a -56.0% margin of safety versus today's $322.30. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is West Pharmaceutical Services Inc's revenue?
West Pharmaceutical Services Inc's trailing twelve-month revenue is $3.22B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
West Pharmaceutical Services Inc's Altman Z-Score is 4.73, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio7.21x
ROE18.15%
Beta1.18
50D MA$299.45
200D MA$270.00
Shares out0.07B
Float0.07B
Short ratio—
Avg volume0.9M
Performance
1 week+0.00%
1 month+3.83%
3 months+30.87%
YTD+14.31%
1 year—
3 years—
5 years—